Welcome to our dedicated page for C21 Investments SEC filings (Ticker: CXXIF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The C21 Investments Inc. (CXXIF) SEC filings page on Stock Titan brings together the company’s U.S. regulatory disclosures as a foreign private issuer. C21 files reports on Form 6-K and Form 20-F under the Securities Exchange Act of 1934 in connection with its listing on the OTCQX market and its operations as a vertically integrated cannabis company.
According to a Form 6-K dated November 2025, C21 submits interim condensed consolidated financial statements and management’s discussion and analysis for periods such as the three and six months ended September 30, along with CEO and CFO certifications. These filings provide detail on the company’s performance from cultivating, processing and distributing cannabis and hemp-derived consumer products, as well as its activities related to assets like Silver State Relief and Silver State Cultivation in Nevada and its legacy Oregon brands.
On this page, investors can review Form 6-K submissions that may include financial statements, MD&A, news releases and other information the company furnishes to the SEC. Annual information is provided through Form 20-F and related transition reports, particularly in connection with C21’s change of financial year-end from January 31 to March 31 as described in its public announcements.
Stock Titan enhances these filings with AI-powered summaries that explain the key points in plain language, helping readers interpret complex financial and legal disclosures. Real-time updates from EDGAR mean new 6-K and 20-F filings appear promptly, while access to insider-related information, where applicable through forms such as Form 4 filed by insiders in the U.S. system, can help users monitor trading by company officers and directors. This page is intended as a convenient way to review C21’s regulatory history and ongoing reporting in one place.
C21 Investments Inc. reported third-quarter revenue of
The company generated Income from Operations of
Current liabilities decreased to
C21 Investments Inc. reports Q3 results for the three and nine months ended December 31, 2025, showing modest growth but continued net losses. Quarterly revenue reached $8.14 million, up from $7.91 million a year earlier, driven mainly by Nevada retail sales and the new South Reno dispensary. For the nine-month period, revenue rose to $25.16 million from $22.01 million, while income from operations improved to $1.79 million from $0.44 million.
Despite stronger operations, heavy interest, accretion, and especially income taxes kept the company in the red, with a Q3 net loss of $0.61 million and a nine-month loss of $1.86 million. The effective tax rate reached 299% year-to-date due to U.S. cannabis tax rules, and an uncertain tax position was recorded. C21 generated $0.96 million of operating cash from continuing operations over nine months and ended with cash of $2.42 million and a working capital surplus of $2.01 million.
During the period, C21 closed a $3.5 million South Reno dispensary asset acquisition funded by a C$4 million convertible debenture financing, expanded its Nevada lease portfolio, and continued normal course issuer bid share repurchases. It also settled long-running Eco Firma Farms litigation with a $2.4 million cash obligation and agreement to issue 555,793 shares, offset by extinguishing $1.77 million of related liabilities.